Viking Therapeutics, Inc.
VKTX
Rank in Stocks
#4529
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Share Price
$26.66
Market Cap
$3.39B
Change (1 day)
-0.19%
Change (1 year)
-19.16%
Country
US
Trade Viking Therapeutics, Inc. (VKTX)
Category
Healthcare
Stock split history for Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. stock (symbol: VKTX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One VKTX share bought prior to Oct 21, 2026 would equal to 0 VKTX shares today.
The most recent stock split occurred on Oct 21, 2026.
One VKTX share bought prior to Oct 21, 2026 would equal to 0 VKTX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
